[Studies on molecular markers for hemostasis and thrombosis in various renal diseases].
In order to clarify the abnormalities of blood coagulation and fibrinolysis in patients with various renal diseases, some molecular markers for hemostasis and thrombosis were examined in comparison with those of the patients with disseminated intravascular coagulation. The results were as follows: 1) PIC was significantly higher in the patients with CGN, NS, SLE, HD and DIC than normal subjects. 2) TAT was significantly higher in the patients with CGN, NS, HD and DIC. 3) SFMC was significantly higher only in the patients of DIC. 4) FDP and FDP-E were significantly higher in the patients with HD and DIC. 5) D-dimer was significantly higher in the patients with CGN, CRF, HD and DIC. These results suggested that the abnormalities of blood coagulation and fibrinolysis in patients with various renal diseases are relatively mild, and situated between the normal subjects and patients with DIC.
Shibata
T
T
Second Department of Internal Medicine, Medical College of Oita, Japan.
Ishii
T
T
Tomo
T
T
Kaneko
K
K
Nasu
M
M
Magari
Y
Y
Fukushima
K
K
D000328:Adult; D000368:Aged; D000933:Antifibrinolytic Agents / Q000032:analysis*; D000990:Antithrombin III / Q000032:analysis*; D015415:Biomarkers / Q000097:blood; D001777:Blood Coagulation; D004211:Disseminated Intravascular Coagulation / Q000097:blood; D005338:Fibrin Fibrinogen Degradation Products / Q000032:analysis*; D005341:Fibrinolysin / Q000032:analysis*; D005342:Fibrinolysis; D006487:Hemostasis; D006801:Humans; D007674:Kidney Diseases / Q000097:blood*; D008875:Middle Aged; D010447:Peptide Hydrolases / Q000032:analysis*; D000979:alpha-2-Antiplasmin
D000933:Antifibrinolytic Agents; D015415:Biomarkers; D005338:Fibrin Fibrinogen Degradation Products; D000979:alpha-2-Antiplasmin; C046193:antithrombin III-protease complex; C011468:fibrinmonomer; C037742:plasmin-plasmin inhibitor complex; D000990:Antithrombin III; D010447:Peptide Hydrolases; D005341:Fibrinolysin